Small interfering RNA (siRNA) Therapeutics Market Analysis 2016: Competitive Landscape, Technology and Pipeline Insights

The Report, “Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2016” depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.

This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.

There are 15+ active companies dealing with 85+ siRNA therapies. Mostly siRNA is being studied for oncology area with 27 siRNA therapies under development by major pharma companies followed by 14 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 23 siRNA are in clinical stage of development with many mid-stage products.

Complete Report Spread across 350 pages with 14 Figures Now Available. Get Inquired on This Report http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=95084

Scope

• Coverage of global siRNA therapies under development across the globe
• Competitive landscape of investigational products for key players and key therapy areas
• The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies.
• Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
• Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline.
• Report analyzes the different emerging delivery technologies by companies and products under development.

Order a Copy of This Report at http://www.lifescienceindustryresearch.com/purchase?rname=95084

Table of Contents

Executive Summary

Small interfering RNA (siRNA) Therapeutics Overview

Introduction

Historical Development:

siRNA: Mode of Action

siRNA Technology &Delivery methods

SiRNA & its Applications in Gene Silencing:

Commercial Assessment

Drivers:

Barriers:

siRNA Therapeutics: Technology Analysis

siRNA Technology & Companies Current Scenario

Companies & Technologies

siRNA Technologies & Products

siRNA Therapeutics: Collaborations Analysis

siRNA Theraputics Collaborations & Deals

siRNA Therapeutics Licensing Deals:

siRNA Therapeutics Acquisition Deals

siRNA Therapeutics: Pipeline Analysis

siRNA Theraputics Therapy Area Analysis

siRNA Therpeutics Clinical Trials Analysis

siRNA Therapeutics &USFDA/EMA Designations

Pipeline Overview

Last Stage Products (Phase III)

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I and IND)

Comparative Analysis

Pre-Clinical and Discovery Products

Comparative Analysis

Therapeutic Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Route of Administration

Discontinued Products

Dormant Products

Companies involved in Therapeutics Development

Appendix

Methodology

Consulting Services

About Us
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.

Contact us ([email protected] / + 1 888 391 5441) for any of your research requirements or topics of interest. Our sales & research associates will be happy to help you find relevant market data.